Evidence map›Paper›PMID 40832875›Full record

Observational studyJournal of the European Academy of Dermatology and Venereology : JEADV2025

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce.

A H Musters, L A A Gerbens, L van der Gang, M A Middelkamp-Hup, W Ouwerkerk, D J Hijnen, E Haufe, L Heinrich, T Werfel, S Weidinger and 20 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

A H MustersDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6209-4554
L A A GerbensDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
L van der GangDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
M A Middelkamp-HupDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
W OuwerkerkDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
D J HijnenDepartment of Dermatology, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-3379-3425
E HaufeCenter for Evidence-Based Health Care (ZEGV), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
L HeinrichCenter for Evidence-Based Health Care (ZEGV), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
T WerfelDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
S WeidingerDepartment of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0003-3944-252X
J SchmittCenter for Evidence-Based Health Care (ZEGV), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
A SvedbomDepartment of Dermatology, Karolinska University Hospital, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-2596-1679
E K JohanssonDepartment of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
M BradleyDepartment of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
L B von KobyletzkiOccupational and Environmental Dermatology, Malmö, Lund University, Lund, Sweden.
I VittrupDepartment of Dermatology and Venereology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
I F RugeDepartment of Dermatology and Venereology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-3914-360X
J P ThyssenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-3770-1743
C VestergaardDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0001-6485-3158
J M CarrascosaDermatology Department, Hospital Universitari Germans Trias i Pujol, Germans Trias I Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-4266-0771
M de VegaResearch Unit, Academia Española de Dermatologia y Venereologia, Madrid, Spain.
I García-DovalResearch Unit, Academia Española de Dermatologia y Venereologia, Madrid, Spain.
A ChiricozziDermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
L StingeniDermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0001-7919-8141
P Calzavara-PintonDepartment of Dermatology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
M R Ardern-JonesClinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
N J ReynoldsInstitute of Translational and Clinical Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
C FlohrPaediatric & Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.ORCID https://orcid.org/0000-0003-4884-6286
P I SpulsDepartment of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).

objectivesThis study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.

methodsData from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).

resultsThe analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.

conclusionsThis pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.

Indexed as

Dermatitis, AtopicRegistriesAdolescentAdrenal Cortex HormonesAdultAntibodies, Monoclonal, HumanizedChildDermatologic AgentsEuropeFemaleHumansMaleMiddle AgedPhototherapySeverity of Illness IndexYoung AdultAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedDermatologic Agentsatopic dermatitisatopic eczemabaselinedemographicsdisease burdendisease severitypatient‐reported outcomesphototherapyreal‐world dataregistrysystemic immunomodulating treatment

Identifiers

PMID40832875
PMCPMC12645184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.